Skip to main content

Advertisement

SpringerLink
Log in

Public biotech 2018—the numbers

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Public companies continued to ride the crest of the wave of financing, licensing deals and regulatory approvals, but clouds may be looming on the horizon for the biggest biotech players. Chris Morrison and Riku Lähteenmäki report.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Public biotech barometers.
Fig. 2: IPOs.
Fig. 3: Global biotech financing.
Fig. 4: NASDAQ biotech index over time.

Author information

Authors and Affiliations

  1. Yardley, Pennsylvania, USA

    Chris Morrison

  2. Turku, Finland

    Riku Lähteenmäki

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chris Morrison.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech 2018—the numbers. Nat Biotechnol 37, 714–721 (2019). https://doi.org/10.1038/s41587-019-0170-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0170-7

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation